Core Viewpoint - BellRing Brands, Inc. (NYSE: BRBR) experienced a significant share price decline of approximately 19% following the announcement of anticipated reductions in retailer inventory levels during its Q2 2025 earnings call, raising concerns about the company's sales practices and consumer demand for its products [1][4]. Company Overview - BellRing Brands is a consumer products holding company that specializes in ready-to-drink (RTD) protein shakes and powders, with its primary brands being Premier Protein and Dymatize [3]. Financial Performance - During the Q2 2025 earnings call, BellRing indicated that it expected "third quarter reductions in retailer trade inventory levels," which would pose a mid-single-digit headwind to its growth [4]. - The company revised its Q3 net sales growth expectations to low-single-digits, attributing Premier Protein as the main driver while other products were expected to remain flat or decline [4]. Investigation Details - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether BellRing Brands may have violated securities laws related to its sales practices, particularly concerning the strength of consumer demand and retail inventory levels [2][5]. - The firm is encouraging investors who have suffered substantial losses to come forward and assist in the investigation [2][5].

Core Viewpoint - The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential violations of securities laws following a significant drop in share price due to allegations of illegal practices and misleading marketing [1][2]. Group 1: Investigation Details - The investigation centers on whether Hims & Hers made false or misleading statements and failed to disclose critical information to investors [2]. - Novo Nordisk announced the termination of its relationship with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. - Following the announcement from Novo Nordisk, Hims & Hers shares plummeted by over 32.4% in afternoon trading [2]. Group 2: Company Background - Hims & Hers Health, Inc. is involved in telehealth services and has faced scrutiny regarding its compliance with laws governing the sale of compounded drugs [2]. - The FDA has resolved a shortage of Wegovy® and confirmed that Novo Nordisk is meeting the demand, which has implications for Hims & Hers' business practices [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Tempus AI, Inc. regarding possible violations of federal securities laws and other unlawful business practices [1][2] Group 1: Investigation and Claims - The investigation by Bragar Eagel & Squire, P.C. is on behalf of Tempus stockholders [1] - Spruce Point Capital Management published a report raising concerns about Tempus, including aggressive accounting practices and the background of several board members with troubled companies [2] - Following the report, Tempus's stock price experienced a significant decline during intraday trading on May 28, 2025 [2] Group 2: Company Background - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM [2] - Bragar Eagel & Squire, P.C. is a law firm that represents individual and institutional investors in various types of litigation [4]

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].

Core Viewpoint - The U.S. Department of Justice has filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging illegal kickbacks related to Medicare Advantage plans, leading to a significant drop in SelectQuote's stock price [2]. Group 1: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against SelectQuote on behalf of its stockholders for possible violations of federal securities laws and unlawful business practices [1]. - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. Group 2: Stock Market Impact - Following the announcement of the DOJ lawsuit, SelectQuote's stock price decreased by $0.61 per share, representing a 19.24% decline, closing at $2.56 per share on May 1, 2025 [2].